

NZX & Media Release

8 December, 2014

TruScreen results for the six months to 30 September 2014

TruScreen Sep 2014 half year sales ahead of forecast

Company now listed on NZAX and focusing on Sales

Highlights:

- Sales for the six months to 30 September, 2014 exceed \$400,000
- Sales to China and Latin America underpin commercial activities
- Product development program on track to deliver new refined device in Q3 of the 2015 calendar year
- Listed on NZAX at 11.00am on Wednesday, 12 November, 2014
- Acceptance of New Zealand WAND notification by Medsafe

The world's only EC certified manufacturer of an electro-light tissue differentiating device for the detection of cervical cancer, TruScreen (NZX.TRU) today released its results for the six months to 30 September 2014.

Sales for the six months to 30 September, 2014 were \$413,761, ahead of the company's internal phased forecast of \$350,224, and well ahead of the 31 March 2014 result of \$19,333. Gross profit for the six months to 30 September, 2014 was \$121,339, compared to the 31 March, 2014 result of \$6,732.

TruScreen's net loss for the six months to 30 September, 2014 was **(\$490,570)**. This compares to a net loss at 31 March 2014 of **(\$1,580,177)**.

TruScreen Chairman Mr. Robert Hunter said: "Sales for TruScreen are underpinned by demand from China and Latin America. Sales to China for this period exceeded \$300,000 and Latin American sales exceeded \$50,000. As our commercial activities in these markets grow, and our activities expand in Europe and West Asia, we expect sales to grow in line with our forecasts."

TruScreen Pty Limited

Australian Office: Level 1, 1 Jamison Street, Sydney, NSW, 2000 / GPO Box 3904, Sydney, NSW, 2001
Tel: 02 9299 8977 / Fax: 02 9262 4644 / Website: www.TruScreen.com

A subsidiary of TruScreen New Zealand

“In addition, not only has our current device had its WAND notification accepted by MEDSAFE in our home market, New Zealand, we are on track to deliver our new refined model to the market in Q3 of the 2015 calendar year. This new model, with its improved usability and performance, will have a significant effect upon our expansion of global sales.”

Outlook

TruScreen CEO Mr. Martin Dillon said “TruScreen is optimistic for our prospects in the year ahead. We have put in place the groundwork for sales in East Asia, West Asia, Central and South America and Europe. We have a product development program that will deliver to the market an improved device with enhanced usability and performance”.

Contact

Martin Dillon
TruScreen Chief Executive Officer
eMail: martindillon@truscreen.com

About TruScreen: www.truscreen.com

TruScreen Limited (NZX.TRU) is a New Zealand company whose operations specialize in the research, development and commercialization of electro-light technologies for the identification of cancerous tissue.

TruScreen is currently targeting the screening and treatment of cervical cancer but the TruScreen technology has the potential of being used to identify other cancers such as bowel, oral and pharyngeal cancers.

TruScreen currently exports its technology to Asia, Europe and Latin America.

TruScreen Pty Limited

Australian Office: Level 1, 1 Jamison Street, Sydney, NSW, 2000 / GPO Box 3904, Sydney, NSW, 2001
Tel: 02 9299 8977 / Fax: 02 9262 4644 / Website: www.TruScreen.com

A subsidiary of TruScreen New Zealand